Pulmonx Corporation
NASDAQ:LUNGMedical - Devices
+$0.05 today
- Market cap
- $117.15M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$1.27
Volume 0.48M
Average 0.44M
LUNG Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Pulmonx CorporationNASDAQ: LUNG
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 17.4% from a year ago
Cash & equivalents stood at $61.57M at the end of Q1 FY2026, down 17.4% from a year earlier and down 12.1% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.
Context
- Cash & equivalents amounted to 51.3% of total assets at the end of Q1 FY2026, up 1.9 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -17.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 70.01M USD
- Year-over-year change
- -1.3%
- 4-year CAGR
- -17.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70.01M | -1.3% |
| FY2024 | 2024-12-31 | 70.91M | -15.1% |
| FY2023 | 2023-12-31 | 83.55M | -17.9% |
| FY2022 | 2022-12-31 | 101.74M | -31.5% |
| FY2021 | 2021-12-31 | 148.48M | — |
Cash & Equivalents vs competitors
How LUNG compares with its peers on the latest reported figures
- LUNG's Mar 2026 cash & equivalents of $61.57M is the 3rd highest of the 10 companies compared; the peer median is $39.13M.
- Its year-over-year change of -17.4% is the 9th highest of 10, against a peer median of -3.7%.
- Cash & equivalents amounts to 51.3% of total assets for LUNG, versus a peer median of 40.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $186.63M | +1204.7% | -47.5% | 98.4% | |
| Mar 2026 | $128.06M | -16.9% | +8.3% | 63.4% | |
| Mar 2026 | $61.57M | -17.4% | -11.7% | 51.3% | |
| Mar 2026 | $50.75M | +76.8% | +6.9% | 28.2% | |
| Mar 2026 | $40.78M | +23.2% | -33.3% | 67.6% | |
| Mar 2026 | $39.13M | -23.8% | -29.5% | 40.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M | -13.0% | +12.0% | 31.6% |
| Mar 2026 | $33.71M | -3.7% | -46.0% | 16.0% | |
| Jun 2026 | $30.42M | -13.0% | +6.6% | 50.9% | |
| Mar 2026 | $9.78M | +750.3% | -13.5% | 4.2% | |
| Peer median (excluding LUNG) | $39.13M | -3.7% | -13.5% | 40.5% | |
Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 148.48M | 101.74M | 83.55M | 70.91M | 70.01M |
| Short-term Investments | 31.56M | 39.4M | 33.56M | 30.58M | 0 |
| Net Receivables | 6.92M | 9.28M | 13.02M | 13.79M | 12.07M |
| Inventory | 16.29M | 14.56M | 16.74M | 16.92M | 15.85M |
| Other Current Assets | 578K | 521K | 741K | 1.39M | 3.76M |
| Total Current Assets | 208M | 168.95M | 150.42M | 136.25M | 101.68M |
| Property, Plant & Equipment (Net) | 12.89M | 10.5M | 7.43M | 21.45M | 20.25M |
| Goodwill | 2.33M | 2.33M | 2.33M | 2.33M | 2.33M |
| Intangible Assets | 277K | 154K | 31K | 0 | 0 |
| Long-term Investments | 10.94M | 5.92M | 14.39M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 731K | 5.81M | 3.17M | 2.82M | 5.03M |
| Total Non-current Assets | 27.17M | 24.72M | 27.36M | 26.6M | 27.61M |
| Total Assets | 235.17M | 193.68M | 177.78M | 162.85M | 129.29M |
| Account Payables | 1.58M | 1.76M | 1.5M | 3.83M | 3.91M |
| Short-term Debt | 91K | 90K | 2.16M | 3.18M | 1.32M |
| Tax Payables | 877K | 646K | 93K | 876K | 0 |
| Deferred Revenue | 163K | 120K | 104K | 135K | 18K |
| Other Current Liabilities | 4.74M | 4.97M | 7.88M | 6.89M | 4.98M |
| Total Current Liabilities | 17.55M | 18.49M | 23.16M | 24.44M | 20.06M |
| Long-term Debt | 17.32M | 17.23M | 35.09M | 34M | 36.99M |
| Deferred Tax Liabilities | 37K | 94K | 114K | 87K | 69K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 179K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 24.38M | 21.18M | 36.31M | 52.6M | 55.12M |
| Total Liabilities | 41.93M | 39.67M | 59.47M | 77.04M | 75.18M |
| Common Stock | 37K | 38K | 39K | 40K | 42K |
| Retained Earnings | (291.4M) | (350.32M) | (411.16M) | (467.56M) | (521.56M) |
| Accumulated OCI | 1.71M | 1.58M | 2.64M | 2.11M | 2.36M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 193.24M | 154.01M | 118.32M | 85.81M | 54.12M |
| Total Debt | 26.46M | 24.4M | 41.42M | 56.47M | 56.36M |
| Net Debt | (122.02M) | (77.33M) | (42.12M) | (14.43M) | (13.65M) |
Pulmonx Corporation
NASDAQ:LUNG
Intrinsic Alpha fair value
Locked
Current Price
$2.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.